Royce & Associates LP Cuts Holdings in Palvella Therapeutics, Inc. $PVLA

Royce & Associates LP cut its position in shares of Palvella Therapeutics, Inc. (NASDAQ:PVLA) by 39.4% during the 4th quarter, Holdings Channel reports. The firm owned 30,010 shares of the company’s stock after selling 19,499 shares during the quarter. Royce & Associates LP’s holdings in Palvella Therapeutics were worth $3,141,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in PVLA. First Light Asset Management LLC purchased a new position in Palvella Therapeutics in the third quarter valued at about $33,949,000. Federated Hermes Inc. purchased a new position in Palvella Therapeutics in the third quarter valued at about $21,255,000. Vanguard Group Inc. boosted its stake in Palvella Therapeutics by 202.0% in the third quarter. Vanguard Group Inc. now owns 494,656 shares of the company’s stock valued at $31,010,000 after acquiring an additional 330,847 shares during the last quarter. Jennison Associates LLC boosted its stake in Palvella Therapeutics by 262.4% in the fourth quarter. Jennison Associates LLC now owns 387,483 shares of the company’s stock valued at $40,558,000 after acquiring an additional 280,573 shares during the last quarter. Finally, Millennium Management LLC purchased a new position in Palvella Therapeutics in the first quarter valued at about $7,553,000. 40.11% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on PVLA. HC Wainwright boosted their target price on shares of Palvella Therapeutics from $255.00 to $270.00 and gave the company a “buy” rating in a research note on Tuesday, March 24th. Truist Financial set a $210.00 target price on shares of Palvella Therapeutics in a research note on Tuesday, February 24th. BTIG Research boosted their target price on shares of Palvella Therapeutics from $192.00 to $215.00 and gave the company a “buy” rating in a research note on Wednesday, February 25th. Wall Street Zen cut shares of Palvella Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, April 11th. Finally, TD Cowen reiterated a “buy” rating on shares of Palvella Therapeutics in a research note on Monday, February 2nd. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $199.53.

Palvella Therapeutics Trading Up 2.2%

Shares of PVLA stock opened at $118.46 on Friday. The stock has a market capitalization of $1.70 billion, a P/E ratio of -28.41 and a beta of -0.13. The firm’s 50 day moving average is $121.17 and its 200 day moving average is $106.84. Palvella Therapeutics, Inc. has a 12 month low of $20.20 and a 12 month high of $151.18.

Palvella Therapeutics (NASDAQ:PVLA) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($1.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.30). On average, equities analysts predict that Palvella Therapeutics, Inc. will post -5.26 EPS for the current year.

Insider Activity at Palvella Therapeutics

In related news, COO Kathleen Goin sold 4,302 shares of the company’s stock in a transaction that occurred on Wednesday, March 18th. The shares were sold at an average price of $117.99, for a total transaction of $507,592.98. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 20.50% of the company’s stock.

About Palvella Therapeutics

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.